Vir Non Current Liabilities Total from 2010 to 2024
VIR Stock | USD 8.74 0.28 3.31% |
Non Current Liabilities Total | First Reported 2018-03-31 | Previous Quarter 204.8 M | Current Value 194.4 M | Quarterly Volatility 143.4 M |
Check Vir Biotechnology financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Vir main balance sheet or income statement drivers, such as Net Interest Income of 86.5 M, Interest Income of 86.5 M or Discontinued Operations of 0.0, as well as many exotic indicators such as Price To Sales Ratio of 14.87, Dividend Yield of 0.0 or PTB Ratio of 0.89. Vir financial statements analysis is a perfect complement when working with Vir Biotechnology Valuation or Volatility modules.
Vir | Non Current Liabilities Total |
Latest Vir Biotechnology's Non Current Liabilities Total Growth Pattern
Below is the plot of the Non Current Liabilities Total of Vir Biotechnology over the last few years. It is Vir Biotechnology's Non Current Liabilities Total historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Vir Biotechnology's overall financial position and show how it may be relating to other accounts over time.
Non Current Liabilities Total | 10 Years Trend |
|
Non Current Liabilities Total |
Timeline |
Vir Non Current Liabilities Total Regression Statistics
Arithmetic Mean | 244,737,644 | |
Geometric Mean | 214,414,005 | |
Coefficient Of Variation | 38.10 | |
Mean Deviation | 79,010,428 | |
Median | 308,044,000 | |
Standard Deviation | 93,253,757 | |
Sample Variance | 8696.3T | |
Range | 301.9M | |
R-Value | (0.67) | |
Mean Square Error | 5221.7T | |
R-Squared | 0.44 | |
Significance | 0.01 | |
Slope | (13,869,994) | |
Total Sum of Squares | 121747.7T |
Vir Non Current Liabilities Total History
About Vir Biotechnology Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include Vir Biotechnology income statement, its balance sheet, and the statement of cash flows. Vir Biotechnology investors use historical funamental indicators, such as Vir Biotechnology's Non Current Liabilities Total, to determine how well the company is positioned to perform in the future. Although Vir Biotechnology investors may use each financial statement separately, they are all related. The changes in Vir Biotechnology's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Vir Biotechnology's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Vir Biotechnology Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Vir Biotechnology. Please read more on our technical analysis and fundamental analysis pages.
Last Reported | Projected for Next Year | ||
Non Current Liabilities Total | 194.4 M | 155.4 M |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Vir Biotechnology in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Vir Biotechnology's short interest history, or implied volatility extrapolated from Vir Biotechnology options trading.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.MSFT | Microsoft | |
CRM | Salesforce | |
GOOG | Alphabet Inc Class C |
Check out the analysis of Vir Biotechnology Correlation against competitors. To learn how to invest in Vir Stock, please use our How to Invest in Vir Biotechnology guide.You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Complementary Tools for Vir Stock analysis
When running Vir Biotechnology's price analysis, check to measure Vir Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vir Biotechnology is operating at the current time. Most of Vir Biotechnology's value examination focuses on studying past and present price action to predict the probability of Vir Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vir Biotechnology's price. Additionally, you may evaluate how the addition of Vir Biotechnology to your portfolios can decrease your overall portfolio volatility.
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
Content Syndication Quickly integrate customizable finance content to your own investment portal | |
CEOs Directory Screen CEOs from public companies around the world | |
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years |
Is Vir Biotechnology's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Vir Biotechnology. If investors know Vir will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Vir Biotechnology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.585 | Earnings Share (4.59) | Revenue Per Share 0.643 | Quarterly Revenue Growth (0.66) | Return On Assets (0.17) |
The market value of Vir Biotechnology is measured differently than its book value, which is the value of Vir that is recorded on the company's balance sheet. Investors also form their own opinion of Vir Biotechnology's value that differs from its market value or its book value, called intrinsic value, which is Vir Biotechnology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Vir Biotechnology's market value can be influenced by many factors that don't directly affect Vir Biotechnology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Vir Biotechnology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Vir Biotechnology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Vir Biotechnology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.